Compounded semaglutide vs brand name Wegovy: what is the real difference?

Short answer

• Wegovy is the brand‑name, FDA‑approved semaglutide product (Novo Nordisk) with clinical trials, a specific dosing schedule for weight loss (up to 2.4 mg weekly), a proprietary injection pen, and regulated manufacturing/quality controls.
• “Compounded semaglutide” is made by compounding pharmacies or clinics from bulk semaglutide API or repackaged drug; it is not FDA‑approved as a copy of Wegovy, may be cheaper, but carries greater uncertainty about dose, purity, sterility, device, and clinical equivalence.

Why that matters — key differences

1. Regulatory status and evidence

• Wegovy: FDA‑approved for chronic weight management, backed by randomized clinical trials showing efficacy and safety at the approved dosing regimen.
• Compounded semaglutide: not FDA‑approved as a Wegovy equivalent. There are no large trials proving that a specific compounded formulation or administration method performs the same in safety or effectiveness.

1. Quality, potency and purity

• Wegovy is manufactured under strict GMP controls and lot‑tested.
• Compounded products depend on the pharmacy’s processes. Risks include wrong dose, inconsistent potency, impurities, or contamination unless the pharmacy performs validated testing and provides certificates of analysis (COAs).

1. Sterility and infection risk

• Wegovy pens are sterile and intended for single‑patient use with validated sterility.
• Poorly prepared injectable compounding can introduce contamination (bacterial/fungal) if not done under proper sterile conditions.

1. Dosing, titration and device differences

• Wegovy uses a dedicated prefilled pen with regulated dose steps; dosing/titration schedules used in trials are matched to that device.
• Compounded semaglutide may be provided in syringes, vials, or non‑standard pens, making accurate self‑dosing and titration harder and increasing error risk.

1. Formulation/excipients and stability

• Different excipients or handling can change stability, shelf life, and possibly absorption.
• Improper storage/transport (cold chain) can degrade semaglutide.

1. Safety monitoring and pharmacovigilance

• Adverse events from Wegovy are tracked via post‑marketing surveillance; compounded products have less robust monitoring and fewer guarantees about lot tracing.

1. Cost and access

• Wegovy is expensive (often thousands per month without coverage), but has manufacturer savings programs and sometimes insurance coverage.
• Compounded semaglutide is frequently cheaper and available through clinics or compounding pharmacies; that cost advantage is the main reason people choose it.

1. Legal and regulatory cautions

• FDA has warned about some compounded semaglutide and states regulate compounding differently. Some compounding that effectively reproduces an FDA‑approved product may be restricted.

If you’re considering compounded semaglutide — precautions and questions to ask

• Use a reputable pharmacy: choose a licensed compounding pharmacy, preferably PCAB‑accredited (Pharmacy Compounding Accreditation Board) or an FDA‑registered outsourcing facility (503B) if available.
• Ask for documentation: COA for potency/purity, sterility test results, source of the active pharmaceutical ingredient (API), lot numbers, and expiration/stability data.
• Ask about the formulation and device: how is it packaged, how will you titrate doses, and who trains you on injections?
• Ask about storage and cold‑chain handling.
• Confirm liability/recourse and what happens if there’s a suspected adverse event.
• Avoid buying semaglutide from unknown online sellers or clinics without transparent lab testing — risk of counterfeit or contaminated products is real.

Practical recommendation

• For the best‑known safety profile and to use a product that matches the randomized trial data, choose Wegovy (Novo Nordisk) when you can.
• If cost or access makes Wegovy impossible, discuss compounded semaglutide with your clinician. If you proceed, only use a reputable, accredited pharmacy/outsourcing facility and require COAs and sterility documentation. Your clinician should monitor you closely for efficacy and side effects.

Other related brand names to know

• Wegovy (Novo Nordisk) — FDA‑approved for weight loss (2.4 mg weekly regimen).
• Ozempic (Novo Nordisk) — semaglutide for type 2 diabetes; often used off‑label at different doses for weight loss but not identical to Wegovy’s dosing schedule.
• Rybelsus — oral semaglutide for diabetes (different formulation and dosing).

Talk with your prescriber or pharmacist about clinical goals, cost/coverage options (Novo Nordisk often has patient support programs/savings), and the risks you’re willing to accept. If you want, I can list questions to ask a compounding pharmacy or give resources for Wegovy assistance programs.